Genetics and tailored therapy in cardiovascular disease.
作者信息
Doevendans P A, Asselbergs F W
机构信息
Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, the Netherlands.
出版信息
Neth Heart J. 2012 Jan;20(1):3-4. doi: 10.1007/s12471-011-0231-0.
Abstract
摘要
相似文献
1
Genetics and tailored therapy in cardiovascular disease.心血管疾病的遗传学与个体化治疗
Neth Heart J. 2012 Jan;20(1):3-4. doi: 10.1007/s12471-011-0231-0.
2
Genetics and pharmacogenetics in the diagnosis and therapy of cardiovascular diseases.遗传学和药物遗传学在心血管疾病诊断与治疗中的应用
Acta Biomed. 2019 Sep 30;90(10-S):7-19. doi: 10.23750/abm.v90i10-S.8748.
3
The TTCYB Study Protocol: A Tailored Print Message Intervention to Improve Cardiovascular Patients' Lifestyles.TTCYB 研究方案：一项定制印刷信息干预措施，以改善心血管病患者的生活方式。
Int J Environ Res Public Health. 2020 Apr 23;17(8):2919. doi: 10.3390/ijerph17082919.
4
Pharmacogenomics and drug response in cardiovascular disorders.心血管疾病中的药物基因组学与药物反应
Pharmacogenomics. 2004 Oct;5(7):779-802. doi: 10.1517/14622416.5.7.779.
5
Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.经皮冠状动脉介入治疗术后急性冠状动脉综合征患者个体化抗血小板治疗的疗效和安全性：一项单中心、随机、可行性研究。
J Geriatr Cardiol. 2015 Jan;12(1):23-9. doi: 10.11909/j.issn.1671-5411.2015.01.003.
6
Personalized prevention approach with use of a web-based cardiovascular risk assessment with tailored lifestyle follow-up in primary care practice--a pilot study.在初级保健实践中采用基于网络的心血管风险评估并进行个性化生活方式随访的个性化预防方法——一项试点研究。
Eur J Prev Cardiol. 2016 Mar;23(5):544-51. doi: 10.1177/2047487315591441. Epub 2015 Jun 16.
7
Tailored, iterative, printed dietary feedback is as effective as group education in improving dietary behaviours: results from a randomised control trial in middle-aged adults with cardiovascular risk factors.个体化、迭代式、打印版饮食反馈与群体教育在改善饮食行为方面同样有效：心血管风险因素的中年成年人中一项随机对照试验的结果。
Int J Behav Nutr Phys Act. 2011 May 20;8:43. doi: 10.1186/1479-5868-8-43.
8
Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease.终末期肾病的遗传学、基因组学和精准医学。
Semin Nephrol. 2018 Jul;38(4):317-324. doi: 10.1016/j.semnephrol.2018.05.002.
9
Effects of internet-based tailored advice on the use of cholesterol-lowering interventions: a randomized controlled trial.基于互联网的个性化建议对降胆固醇干预措施使用情况的影响：一项随机对照试验。
J Med Internet Res. 2010 Sep 13;12(3):e42. doi: 10.2196/jmir.1364.
10
Tailored Interventions to Improve Medication Adherence for Cardiovascular Diseases.为改善心血管疾病药物依从性而量身定制的干预措施。
Front Pharmacol. 2020 Nov 13;11:510339. doi: 10.3389/fphar.2020.510339. eCollection 2020.
引用本文的文献
1
Cardiovascular genetics: technological advancements and applicability for dilated cardiomyopathy.心血管遗传学：技术进步及其在扩张型心肌病中的适用性。
Neth Heart J. 2015 Jul;23(7-8):356-62. doi: 10.1007/s12471-015-0700-y.
本文引用的文献
1
Evaluation of newborn screening bloodspot-based genetic testing as second tier screen for bedside newborn hearing screening.基于新生儿筛查血斑的基因检测作为床边新生儿听力筛查的二级筛查的评估。
Genet Med. 2011 Dec;13(12):1006-10. doi: 10.1097/GIM.0b013e318226fc2e.
2
Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study.个体化治疗血管紧张素转换酶（ACE）抑制剂在稳定型冠状动脉疾病中的应用：PERindopril GENEtic association（PERGENE）研究主要结果概述。
Neth Heart J. 2012 Jan;20(1):24-32. doi: 10.1007/s12471-011-0173-6.
3
Pharmacogenetics, pharmacogenomics, and individualized medicine.药物遗传学、药物基因组学与个体化医学。
Pharmacol Rev. 2011 Jun;63(2):437-59. doi: 10.1124/pr.110.003533. Epub 2011 Mar 24.
4
Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems.心血管风险与肾素-血管紧张素、缓激肽和纤溶系统基因多态性之间的相互作用有关。
PLoS One. 2010 Sep 15;5(9):e12757. doi: 10.1371/journal.pone.0012757.
5
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.CYP2C19*2 和 CYP2C9*3 等位基因与支架血栓形成相关：一项病例对照研究。
Eur Heart J. 2010 Dec;31(24):3046-53. doi: 10.1093/eurheartj/ehq321. Epub 2010 Sep 10.
6
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.培哚普利基因关联研究（PERGENE）的原理与设计：稳定性冠心病患者血管紧张素转换酶抑制剂治疗的药物遗传学分析
Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. Epub 2008 Dec 10.
7
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).培哚普利对稳定型冠心病患者心血管事件的降低疗效：随机、双盲、安慰剂对照、多中心试验（EUROPA研究）
Lancet. 2003 Sep 6;362(9386):782-8. doi: 10.1016/s0140-6736(03)14286-9.
8
Unravelling the pathophysiology of heart failure through human genomics.通过人类基因组学揭示心力衰竭的病理生理学机制。
Eur J Clin Invest. 2001 May;31(5):378-9. doi: 10.1046/j.1365-2362.2001.00804.x.
9
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.雌激素加孕激素用于绝经后妇女冠心病二级预防的随机试验。心脏与雌激素/孕激素替代研究（HERS）研究组
JAMA. 1998 Aug 19;280(7):605-13. doi: 10.1001/jama.280.7.605.
Zotero 插件